Compare DexCom, Inc. (DXCM) vs Figma Inc. Class A Common Stock (FIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Figma Inc. Class A Common Stock — how do they compare? DexCom, Inc. trades at $84.82 (market cap $32.09B), while Figma Inc. Class A Common Stock trades at $21.33 (market cap $11.60B). The key difference: DexCom, Inc. is far larger — about 2.8× Figma Inc. Class A Common Stock's market cap, and DexCom, Inc. is trading nearer its 52-week high, Figma Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Figma Inc. Class A Common Stock for 0 Days on average.
| DXCM | FIG | |
|---|---|---|
Market Cap | $32.09B | $11.60B |
Volume | 3,819,730 | 12,281,013 |
Sector | Health | Technology |
52-Week High | $92.34 | $63.82 |
52-Week Low | $54.84 | $16.84 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $31.54B | $10.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $85.06, down 1.0% on the day, with a bullish technical signal and strong fundamental growth. Revenue reached $4.66B in 2025 with a net income margin of 17.93%, and the company has beaten EPS estimates for the last three quarters. Recent news highlights expansion in Type 2 diabetes care and executive promotions, supporting positive sentiment.
The outlook is positive with a consensus price target of $96.14, implying 13% upside. Risks include competition and reimbursement challenges, but robust earnings growth and institutional backing provide a solid foundation for long-term investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Figma Inc. Class A Common Stock
Figma, Inc. is a US software company that operates a collaborative interface design and product development platform used by design and engineering teams to create, prototype, and build digital products.
Read more on FIG →
